Biolase

BIOL · Other

$0.00−$0.0001 (−99.00%)TodayMarket closed · Oct 15, 12:10 PM ET

No price history for this range.

BIOL analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Oct 3, 2024

Bull case

Biolase Inc. projects an annual revenue growth of approximately 6-8% for 2024, targeting revenue between $52-53 million and positive adjusted EBITDA for the year. The company is leveraging its technological leadership to enhance commercial execution through established market development programs, which may foster consistent sales growth. Additionally, potential gross margin improvements could arise from increased sales volume, pricing strategies, reduced production costs, and efficient manufacturing processes.

Bear case

Biolase Inc. has lowered its 2024 revenue growth expectations from an anticipated 6-8% to flat, reflecting a significant downturn in market conditions and leading to a revised revenue estimate of $47.9 million, down from $52.4 million. The majority of the company’s revenue is derived from the United States, a market currently facing challenges that may contribute to this negative outlook. Additionally, regulatory uncertainties pose a risk that could delay or prevent the approval of new products, further impacting the company’s growth potential.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.